Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Sejeong Park  (Park S) 3 Articles
Complications
Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data
Sejeong Park, Sang Youl Rhee, Su Jin Jeong, Kiyoung Kim, Suk Chon, Seung-Young Yu, Jeong-Taek Woo
Diabetes Metab J. 2017;41(5):393-404.   Published online September 5, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.5.393
  • 5,165 View
  • 44 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

This is part of a prospective study carried out as a national project to secure standardized public resources for type 2 diabetes mellitus (T2DM) patients in Korea. We compared various characteristics of long-standing T2DM patients with diabetic retinopathy (DR) and macular edema (ME).

Methods

From September 2014 to July 2015, T2DM patients with disease duration of at least 15 years were recruited at a single university hospital. Clinical data and samples were collected according to the common data elements and standards of procedure developed by the Korean Diabetes Association Research Council. Each participant was assessed by ophthalmologists for DR and ME.

Results

Among 220 registered patients, 183 completed the ophthalmologic assessment. DR was associated with longer disease duration (odds ratio [OR], 1.071; 95% confidence interval [CI], 1.001 to 1.147 for non-proliferative diabetic retinopathy [NPDR]) (OR, 1.142; 95% CI, 1.051 to 1.242 for proliferative diabetic retinopathy [PDR]) and the use of long-acting insulin (OR, 4.559; 95% CI, 1.672 to 12.427 for NPDR) (OR, 4.783; 95% CI, 1.581 to 14.474 for PDR), but a lower prevalence of a family history of cancer (OR, 0.310; 95% CI, 0.119 to 0.809 for NPDR) (OR, 0.206; 95% CI, 0.063 to 0.673 for PDR). ME was associated with higher glycosylated hemoglobin levels (OR, 1.380; 95% CI, 1.032 to 1.845) and the use of rapid-acting insulin (OR, 5.211; 95% CI, 1.445 to 18.794).

Conclusion

Various clinical features were associated with DR and ME. Additional epidemiological and biorepository-based studies using this cohort are being conducted to deepen our understanding of diabetic complications in Korea.

Citations

Citations to this article as recorded by  
  • Diabetic retinopathy related homeostatic dysregulation and its association with mortality among diabetes patients: A cohort study from NHANES
    Wenxiang Li, Zhaoguang Lai, Ningning Tang, Fen Tang, Guangyi Huang, Peng Lu, Li Jiang, Daizai Lei, Fan Xu
    Diabetes Research and Clinical Practice.2024; 207: 111081.     CrossRef
  • Study on the Interaction Between C3 Gene Polymorphism and Environment in Patients with Type 2 Diabetes Combined with Coronary Artery Disease
    Haitang Qiu, Shajidan Abudureyimu, Mengjia Liu, Fen Liu, Ying Gao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1467.     CrossRef
  • Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus
    Milena Cojic, Aleksandra Klisic, Amina Sahmanovic, Nemanja Petrovic, Gordana Kocic
    Scientific Reports.2024;[Epub]     CrossRef
  • Amino acid analysis as a method of discovering biomarkers for diagnosis of diabetes and its complications
    Dan Cai, Biao Hou, Song Lin Xie
    Amino Acids.2023; 55(5): 563.     CrossRef
  • The correlation between peripheral complete blood count parameters and diabetic macular edema in proliferative diabetic retinopathy patients: a cross-sectional study
    Chunyan Lei, Jinyue Gu, Lili Liu, Keren Zhang, Meixia Zhang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • The association between different hypoglycemic regimens and postoperative diabetic macular edema after vitrectomy in the Japanese patients with proliferative diabetic retinopathy
    Chunyan Lei, Yun Zhang, Meixia Zhang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Plasma amino acids and oxylipins as potential multi-biomarkers for predicting diabetic macular edema
    Sang Youl Rhee, Eun Sung Jung, Dong Ho Suh, Su Jin Jeong, Kiyoung Kim, Suk Chon, Seung-Young Yu, Jeong-Taek Woo, Choong Hwan Lee
    Scientific Reports.2021;[Epub]     CrossRef
  • SYSTEMIC FACTORS AND EARLY TREATMENT RESPONSE TO INTRAVITREAL INJECTION FOR DIABETIC MACULAR EDEMA
    Hyeseong Hwang, Hwanho Lee, Jin Young Kim, Suhwan Lee, Eoi Jong Seo, Ju Byung Chae, Dong Yoon Kim
    Retina.2021; 41(6): 1275.     CrossRef
  • Relationship between Clinical Features of Diabetic Retinopathy and Systemic Factors in Patients with Newly Diagnosed Type II Diabetes Mellitus
    Hyeseong Hwang, Jin Young Kim, Tae Keun Oh, Ju Byung Chae, Dong Yoon Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
    Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
    Jun Sung Moon
    Diabetes & Metabolism Journal.2019; 43(6): 911.     CrossRef
  • Prevalence and epidemiological characteristics of patients with diabetic retinopathy in Slovakia: 12-month results from the DIARET SK study
    Marta Ondrejkova, Peter Jackuliak, Emil Martinka, Marian Mokan, James Foley, Jana Fabkova, Karol Gecik, Iveta Tvrda, Miroslav Helbich, Monika Gajdosova, Tomislav Bulum
    PLOS ONE.2019; 14(12): e0223788.     CrossRef
  • Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis
    Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko
    Diabetes & Metabolism Journal.2018; 42(2): 93.     CrossRef
  • Letter: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
    Jae-Seung Yun
    Diabetes & Metabolism Journal.2017; 41(6): 492.     CrossRef
  • Response: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
    Sang Youl Rhee, Jeong-Taek Woo
    Diabetes & Metabolism Journal.2017; 41(6): 494.     CrossRef
Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
Sejeong Park, So Young Park, Sang Youl Rhee
Diabetes Metab J. 2016;40(4):336-337.   Published online August 18, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.4.336
  • 2,852 View
  • 40 Download
PDFPubReader   
Others
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
Sejeong Park, So Young Park, Yu Jin Kim, Soo Min Hong, Suk Chon, Seungjoon Oh, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Sang Youl Rhee
Diabetes Metab J. 2016;40(3):240-247.   Published online April 5, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.3.240
  • 5,422 View
  • 62 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.

Methods

Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.

Results

A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study.

Conclusion

Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.

Citations

Citations to this article as recorded by  
  • Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials
    Dmitry N. Andreev, Igor V. Maev, Dmitry S. Bordin, Svetlana V. Lyamina, Diana T. Dicheva, Aleksei K. Fomenko, Armine S. Bagdasarian
    Consilium Medicum.2022; 24(5): 333.     CrossRef
  • Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy
    A. R. Molchanova, A. I. Dolgushina, A. A. Seljanina
    Experimental and Clinical Gastroenterology.2020; (6): 82.     CrossRef
  • Rebamipide: evidence base for use in gastroenterology
    D. N. Andreev, I. V. Maev
    Terapevticheskii arkhiv.2020; 92(12): 97.     CrossRef
  • Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
    Mohamed Hasif Jaafar, Sher Zaman Safi, Maw-Pin Tan, Sanjay Rampal, Sanjiv Mahadeva
    Digestive Diseases and Sciences.2018; 63(5): 1250.     CrossRef
  • Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2016; 40(4): 334.     CrossRef
  • Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
    Sejeong Park, So Young Park, Sang Youl Rhee
    Diabetes & Metabolism Journal.2016; 40(4): 336.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal